These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37603080)

  • 1. Daily Cannabidiol Administration for 10 Weeks Modulates Hippocampal and Amygdalar Resting-State Functional Connectivity in Cannabis Users: A Functional Magnetic Resonance Imaging Open-Label Clinical Trial.
    Lorenzetti V; McTavish E; Broyd S; van Hell H; Thomson D; Ganella E; Kottaram AR; Beale C; Martin J; Galettis P; Solowij N; Greenwood LM
    Cannabis Cannabinoid Res; 2024 Aug; 9(4):e1108-e1121. PubMed ID: 37603080
    [No Abstract]   [Full Text] [Related]  

  • 2. Dissociable effects of cannabis with and without cannabidiol on the human brain's resting-state functional connectivity.
    Wall MB; Pope R; Freeman TP; Kowalczyk OS; Demetriou L; Mokrysz C; Hindocha C; Lawn W; Bloomfield MA; Freeman AM; Feilding A; Nutt D; Curran HV
    J Psychopharmacol; 2019 Jul; 33(7):822-830. PubMed ID: 31013455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Individual and combined effects of cannabidiol and Δ
    Wall MB; Freeman TP; Hindocha C; Demetriou L; Ertl N; Freeman AM; Jones AP; Lawn W; Pope R; Mokrysz C; Solomons D; Statton B; Walker HR; Yamamori Y; Yang Z; Yim JL; Nutt DJ; Howes OD; Curran HV; Bloomfield MA
    J Psychopharmacol; 2022 Jun; 36(6):732-744. PubMed ID: 35596578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised controlled trial of vaporised Δ
    Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
    Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute effects of different types of cannabis on young adult and adolescent resting-state brain networks.
    Ertl N; Freeman TP; Mokrysz C; Ofori S; Borissova A; Petrilli K; Curran HV; Lawn W; Wall MB
    Neuropsychopharmacology; 2024 Sep; 49(10):1640-1651. PubMed ID: 38806583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabinoid modulation of functional connectivity within regions processing attentional salience.
    Bhattacharyya S; Falkenberg I; Martin-Santos R; Atakan Z; Crippa JA; Giampietro V; Brammer M; McGuire P
    Neuropsychopharmacology; 2015 May; 40(6):1343-52. PubMed ID: 25249057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of cannabinoids on resting state functional brain connectivity: A systematic review.
    Lorenzetti V; Gaillard A; Thomson D; Englund A; Freeman TP
    Neurosci Biobehav Rev; 2023 Feb; 145():105014. PubMed ID: 36563921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged Cannabidiol Treatment Effects on Hippocampal Subfield Volumes in Current Cannabis Users.
    Beale C; Broyd SJ; Chye Y; Suo C; Schira M; Galettis P; Martin JH; Yücel M; Solowij N
    Cannabis Cannabinoid Res; 2018; 3(1):94-107. PubMed ID: 29682609
    [No Abstract]   [Full Text] [Related]  

  • 9. Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing.
    Fusar-Poli P; Crippa JA; Bhattacharyya S; Borgwardt SJ; Allen P; Martin-Santos R; Seal M; Surguladze SA; O'Carrol C; Atakan Z; Zuardi AW; McGuire PK
    Arch Gen Psychiatry; 2009 Jan; 66(1):95-105. PubMed ID: 19124693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic effects of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis in infrequent cannabis users.
    Spindle TR; Cone EJ; Goffi E; Weerts EM; Mitchell JM; Winecker RE; Bigelow GE; Flegel RR; Vandrey R
    Drug Alcohol Depend; 2020 Jun; 211():107937. PubMed ID: 32247649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology.
    Bhattacharyya S; Morrison PD; Fusar-Poli P; Martin-Santos R; Borgwardt S; Winton-Brown T; Nosarti C; O' Carroll CM; Seal M; Allen P; Mehta MA; Stone JM; Tunstall N; Giampietro V; Kapur S; Murray RM; Zuardi AW; Crippa JA; Atakan Z; McGuire PK
    Neuropsychopharmacology; 2010 Feb; 35(3):764-74. PubMed ID: 19924114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trial.
    Arkell TR; Vinckenbosch F; Kevin RC; Theunissen EL; McGregor IS; Ramaekers JG
    JAMA; 2020 Dec; 324(21):2177-2186. PubMed ID: 33258890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis.
    O'Neill A; Wilson R; Blest-Hopley G; Annibale L; Colizzi M; Brammer M; Giampietro V; Bhattacharyya S
    Psychol Med; 2021 Mar; 51(4):596-606. PubMed ID: 31994476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial.
    Zamarripa CA; Spindle TR; Surujunarain R; Weerts EM; Bansal S; Unadkat JD; Paine MF; Vandrey R
    JAMA Netw Open; 2023 Feb; 6(2):e2254752. PubMed ID: 36780161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hippocampal harms, protection and recovery following regular cannabis use.
    Yücel M; Lorenzetti V; Suo C; Zalesky A; Fornito A; Takagi MJ; Lubman DI; Solowij N
    Transl Psychiatry; 2016 Jan; 6(1):e710. PubMed ID: 26756903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opposite Roles for Cannabidiol and δ-9-Tetrahydrocannabinol in Psychotomimetic Effects of Cannabis Extracts: A Naturalistic Controlled Study.
    Sainz-Cort A; Jimenez-Garrido D; Muñoz-Marron E; Viejo-Sobera R; Heeroma J; Bouso JC
    J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):561-570. PubMed ID: 34412109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis 'amotivational' hypotheses.
    Lawn W; Freeman TP; Pope RA; Joye A; Harvey L; Hindocha C; Mokrysz C; Moss A; Wall MB; Bloomfield MA; Das RK; Morgan CJ; Nutt DJ; Curran HV
    Psychopharmacology (Berl); 2016 Oct; 233(19-20):3537-52. PubMed ID: 27585792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users.
    Hindocha C; Freeman TP; Schafer G; Gardener C; Das RK; Morgan CJ; Curran HV
    Eur Neuropsychopharmacol; 2015 Mar; 25(3):325-34. PubMed ID: 25534187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment.
    Englund A; Morrison PD; Nottage J; Hague D; Kane F; Bonaccorso S; Stone JM; Reichenberg A; Brenneisen R; Holt D; Feilding A; Walker L; Murray RM; Kapur S
    J Psychopharmacol; 2013 Jan; 27(1):19-27. PubMed ID: 23042808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being.
    Morgan CJ; Gardener C; Schafer G; Swan S; Demarchi C; Freeman TP; Warrington P; Rupasinghe I; Ramoutar A; Tan N; Wingham G; Lewis S; Curran HV
    Psychol Med; 2012 Feb; 42(2):391-400. PubMed ID: 21798112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.